Sergio Cifuentes Canaval: I’m thrilled to share groundbreaking progress in the treatment of locally advanced cervical cancer (LACC)!
Sergio Cifuentes Canaval, Cancer Research Project Manager at
“I’m thrilled to share groundbreaking progress in the treatment of locally advanced cervical cancer (LACC)! The results from a phase 3 clinical trial, ENGOT-cx11/GOG-3047/KEYNOTE-A18, have demonstrated that the addition of pembrolizumab to standard chemoradiotherapy significantly improved progression-free survival compared to placebo in patients with newly diagnosed, high-risk LACC.
This advancement holds immense promise for improving outcomes and quality of life for women facing this challenging diagnosis.
- Conducted at 176 medical centers across 30 countries.
- Primary endpoint of PFS: 0.70 (95% CI 0.55-0.89, p=0.0020) favoring the pembrolizumab-chemoradiotherapy group.
- mPFS, with 24-month: 68% in the pembrolizumab group vs 57% in the placebo group.
- OS not yet reached statistical significance, with an HR for death of 0.73 (95% CI 0.49-1.07).
- This study marks a significant step forward in the treatment landscape for LACC. We eagerly await further analysis to determine the impact on overall survival.
Congrats to Domenica Lorusso and Ana Oaknin.”
Source: Sergio Cifuentes Canaval/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.